Clinical Scorecard: Reduced Expression of LncRNA GAS8-AS1 Correlates with Early Disease Stages and Lymph Node Metastasis, While Its Silencing Enhances Proliferation, Migration, and Invasion in Differentiated Thyroid Cancer

At a Glance

Key Highlights

• GAS8-AS1 expression significantly downregulated in DTCs compared to normal tissues (p < 0.0001).
• Lower GAS8-AS1 expression associated with early-stage disease (p = 0.03) and lymph node metastasis (p = 0.03).
• Functional studies show GAS8-AS1 knockdown increases proliferation, migration, and invasion.
• Pathway analyses indicate GAS8-AS1 involvement in autophagy, apoptosis, and metastasis.
• Potential role of GAS8-AS1 as a diagnostic and prognostic biomarker in DTCs.

Guideline-Based Recommendations

Diagnosis

• Evaluate GAS8-AS1 expression levels in thyroid cancer patients.

Management

• Consider GAS8-AS1 as a potential therapeutic target in DTC.

Monitoring & Follow-up

• Monitor GAS8-AS1 levels for disease progression and metastasis.

Risks

• Downregulation of GAS8-AS1 may indicate higher risk of aggressive disease.

Patient & Prescribing Data

Patients diagnosed with differentiated thyroid cancer.

Current therapies include surgical resection, radioactive iodine therapy, and targeted therapies for advanced cases.

Clinical Best Practices

• Incorporate GAS8-AS1 expression analysis in the diagnostic workup for DTC.
• Utilize GAS8-AS1 as a biomarker for monitoring disease progression.

Related Resources & Content

• The Cancer Genome Atlas (TCGA) study of thyroid cancer